bioresearch-filters-purificationFeaturedArticles
-
A New Year At Life Science Leader
1/1/2024
Life Science Leader wishes you a happy New Year and announces plans for 2024.
-
Impressions And Takeaways From BPI West 2025
3/27/2025
Editor Tyler Menichiello reviews the most compelling topics and sessions from this year's BioProcess International U.S. West.
-
Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit
9/26/2025
OS Therapies' Dr. Robert Petit discusses the evolving role of immunotherapy in prostate cancer.
-
Why Perfect Clinical Trial Data Is A Dangerous Myth
6/2/2025
Former FDA inspector Kara Harrison reveals clinical trials fail due to overcomplex designs, checklist-driven monitoring that misses critical issues, and lack of focus on what actually matters for patient safety and data integrity.
-
6 Microscopy And Nanopositioning Innovations To Be Aware Of
5/1/2024
Microscopy and nanopositioning go hand in hand, allowing researchers to see objects too small to see with the naked eye. Let’s take a look at three innovations for each of these tiny technologies.
-
Easing Autologous Cell Collection, Automating Manufacturing
1/22/2025
To circumvent the challenges of leukapheresis, CellProthera developed a novel method for collecting therapeutic stem cells from whole blood. CSO Ibon Garitaonandia, Ph.D., discusses the company's mission to streamline manufacturing.
-
Your CDMO's Maintenance, From Roof To Floor And Ever More
10/14/2024
Facility Maintenance –an all-encompassing descriptor. It starts with taking care of an internal ecosphere - everything from roof to floor. It also includes an exosphere – the real estate the facilities sit on, the business parks where they are located, and the communities they reside within. When you are outsourcing, it makes you a part of it all as well. How much do you know about this area of your CDMO’s existence?
-
Rocket Pharma's Modality-Agnostic Approach To Rare Disease
7/24/2024
Rocket Pharmaceuticals’ president, COO, and head of R&D, Dr. Kinnari Patel, discusses the company’s modality-agnostic approach to treating rare diseases.
-
What's In Your DMF?
7/8/2024
Are relevant Drug Master Files (DMFs) at your CDMO in good order or fully under consideration as part of your upcoming new-drug submissions to the FDA or other agencies? “I've lived with this on both sides, as an FDA official and at biopharma organizations,” says Ben Stevens, Director CMC Policy and Advocacy, GSK, and former Branch Chief / Chemistry Reviewer at FDA. Here's what he advises.
-
Antibodies 2025: Venerable & Naked Or Complex & Multi-Specific?
12/19/2024
Antibodies are the biotherapeutic bulwark, the steadfast stalwart in not just oncology, but infectious and chronic inflammatory diseases as well. We consulted with a variety of antibody developers for insight into the challenges and opportunities antibody modalities face in the coming year and beyond.